SATB2 is a novel marker of osteoblastic
differentiation and colorectal adenocarcinoma.
The fusion protein was purified and analyzed for the effects on proliferation and osteoblastic
differentiation of fibroblast MRC-5 and preosteoblast MC3T3-E1 cells using the MTT assay and ALP activity.
In fact, vascular cellular culture studies have been carried out with the intention to describe the effect of Cbfa1 over osteoblastic
differentiation, and they have reported an induced mineralization and OPN expression after inorganic phosphate was added.
Porphyromonas gingivalis lipopolysaccharide inhibits the osteoblastic
differentiation of preosteoblasts by activating Notch1 signaling.
Fluoride treated bioresorbable synthetic nonceramic (corrected) hydroxyapatite promotes proliferation & differentiation of human osteoblastic
Currently, our previous data confirmed that tanshinol attenuates suppression of osteoblastic
differentiation induced by oxidative stress via Wnt/FoxO3a signaling pathway in C2C12 cells and MC3T3-E1 cells, in line with positive control resveratrol, a well-known antioxidant containing polyphenols acid structure similar to tanshinol .
Osteoporosis is a kind of metabolic disorders characterized by the imbalance between osteoblastic
formation and osteoclastic resorption.
Specifically, discernible decreases in trabecular bone mass and osteoblastic
function were observed in response to Pb or HFD.
The conventional or classical os- teosarcoma is the most frequent variant, which develops in the medullary region of the bone and can be subdivided in osteoblastic
, chon- droblastic and fibroblastic histological types, depending on the type of extra-cellular matrix produced by tumour cells.
The case of a relatively frequent benign osteoblastic
tumour, osteoid osteoma at an atypical site is presented.
In osteoblast, strontium (Sr) activates osteoblastogenesis by promoting osteoblastic
cell replication and differentiation, and reducing apoptosis by mechanisms involving activation of CaSR results in enhanced extracellular signal regulated kinases (ERK1/ 2) (17).
Belgian biotechnology company Bone Therapeutics has developed an osteoblastic
(bone-forming) stem cell treatment that could avoid thousands of hip replacements by helping patients 'regrow' damaged bone.